Rossana Segura Lazcano

Research output

Research output per year 2020 2022 2023 2024

• 24 Article
• 4 Review article
• 1 Comment/debate

Research output per year

Research output per year

Search results

• 2024

  A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

  Roland, C. L., Nassif Haddad, E. F., Keung, E. Z., Wang, W-L., Lazar, A. J., Lin, H., Chelvanambi, M., Parra, E. R., Wani, K., Guadagnolo, B. A., Bishop, A. J., Burton, E. M., Hunt, K. K., Torres, K. E., Feig, B. W., Scally, C. P., Lewis, V. O., Bird, J. E., Ratan, R., Araujo, D., & 39 othersZarzour, M. A., Patel, S., Benjamin, R., Conley, A. P., Livingston, J. A., Ravi, V., Tawbi, H., Lin, P. P., Moon, B. S., Satcher, R. L., Mujtaba, B., Witt, R. G., Traweek, R. S., Cope, B., Lazcano, R., Wu, C. C., Zhou, X., Mohammad, M. M., Chu, R. A., Zhang, J., Damania, A., Sahasrabhojane, P., Tate, T., Callahan, K., Nguyen, S., Ingram, D., Morey, R., Crosby, S., Mathew, G., Duncan, S., Lima, C. F., Blay, J. Y., Fridman, W. H., Shaw, K., Wistuba, I., Futreal, A., Ajami, N., Wargo, J. A. & Somaiah, N., 2024, (Accepted/In press) In: Nature Cancer.

  Research output: Contribution to journal › Article › peer-review

• Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides

  Marques-Piubelli, M. L., Navarrete, J., Ledesma, D. A., Hudgens, C. W., Lazcano, R. N., Alani, A., Huen, A., Duvic, M., Nagarajan, P., Aung, P. P., Wistuba, I. I., Curry, J. L., Miranda, R. N. & Torres-Cabala, C. A., Mar 2024, In: Cells. 13, 5, 419.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mycosis Fungoides 100%
  • Up-Regulation 55%
  • Protein 31%
  • Proteins 28%
  • Lactate 26%

• Pan-cancer proteogenomics characterization of tumor immunity

  Clinical Proteomic Tumor Analysis Consortium, Feb 29 2024, In: Cell. 187, 5, p. 1255-1277.e27

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2023

  Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non–Small Cell Lung Cancer

  Francisco-Cruz, A., Rocha, P., Reuben, A., Krishnan, S. N., Das, P., Chen, R., Quek, K., Li, J., Parra, E. R., Solis, L. M., Barua, S., Jiang, M., Lazcano, R., Chow, C. W., Behrens, C., Gumb, C., Little, L., Fukuoka, J., Kalhor, N., Weissferdt, A., & 13 othersKadara, H., Heymach, J. V., Swisher, S., Sepesi, B., Rao, A., Moran, C., Zhang, J., Lee, J. J., Fujimoto, J., Futreal, P. A., Wistuba, I. I., Peterson, C. B. & Zhang, J., Jan 2023, In: Modern Pathology. 36, 1, 100028.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-Small Cell Lung Carcinoma 100%
  • Lymphocytes 77%
  • Recurrence 64%
  • T-Lymphocytes 59%
  • Spatial Analysis 41%
  3 Scopus citations

• Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

  Nassif, E. F., Joseph, C. P., Lazcano, R., Joseph, J. T., Thirasastr, P., Lazar, A. J. & Somaiah, N., Feb 9 2023, In: Frontiers in Oncology. 13, 1046442.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • gemcitabine 100%
  • Sirolimus 95%
  • Sarcoma 84%
  • United States Food and Drug Administration 44%
  • Perivascular Epithelioid Cell Neoplasms 35%

• Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

  Beird, H. C., Wu, C. C., Nakazawa, M., Ingram, D., Daniele, J. R., Lazcano, R., Little, L., Davies, C., Daw, N. C., Wani, K., Wang, W. L., Song, X., Gumbs, C., Zhang, J., Rubin, B., Conley, A., Flanagan, A. M., Lazar, A. J. & Futreal, P. A., Oct 12 2023, In: Human Genetics and Genomics Advances. 4, 4, 100224.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Rhabdomyosarcoma 100%
  • Genome 57%
  • Sarcoma 29%
  • Alveolar Rhabdomyosarcoma 15%
  • Embryonal Rhabdomyosarcoma 15%

• Deep learning integrates histopathology and proteogenomics at a pan-cancer level

  Clinical Proteomic Tumor Analysis Consortium, Sep 19 2023, In: Cell Reports Medicine. 4, 9, 101173.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Proteogenomics 100%
  • Deep Learning 82%
  • Proteomics 36%
  • Histology 31%
  • Machine Learning 22%
  1 Scopus citations

• Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

  Goyal, Y., Busch, G. T., Pillai, M., Li, J., Boe, R. H., Grody, E. I., Chelvanambi, M., Dardani, I. P., Emert, B., Bodkin, N., Braun, J., Fingerman, D., Kaur, A., Jain, N., Ravindran, P. T., Mellis, I. A., Kiani, K., Alicea, G. M., Fane, M. E., Ahmed, S. S., & 15 othersLi, H., Chen, Y., Chai, C., Kaster, J., Witt, R. G., Lazcano, R., Ingram, D. R., Johnson, S. B., Wani, K., Dunagin, M. C., Lazar, A. J., Weeraratna, A. T., Wargo, J. A., Herlyn, M. & Raj, A., Aug 17 2023, In: Nature. 620, 7974, p. 651-659 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pharmaceutical Preparations 100%
  • Neoplasms 77%
  • Therapeutics 39%
  • Clone Cells 34%
  • RNA Sequence Analysis 24%
  23 Scopus citations

• Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

  Clinical Proteomic Tumor Analysis Consortium, Sep 11 2023, In: Cancer cell. 41, 9, p. 1567-1585.e7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • DNA Methylation 100%
  • Epigenomics 37%
  • Neoplasms 32%
  • Methylation 26%
  • Regulon 19%
  3 Scopus citations

• Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

  Chu, Y., Dai, E., Li, Y., Han, G., Pei, G., Ingram, D. R., Thakkar, K., Qin, J. J., Dang, M., Le, X., Hu, C., Deng, Q., Sinjab, A., Gupta, P., Wang, R., Hao, D., Peng, F., Yan, X., Liu, Y., Song, S., & 25 othersZhang, S., Heymach, J. V., Reuben, A., Elamin, Y. Y., Pizzi, M. P., Lu, Y., Lazcano, R., Hu, J., Li, M., Curran, M., Futreal, A., Maitra, A., Jazaeri, A. A., Ajani, J. A., Swanton, C., Cheng, X. D., Abbas, H. A., Gillison, M., Bhat, K., Lazar, A. J., Green, M., Litchfield, K., Kadara, H., Yee, C. & Wang, L., Jun 2023, In: Nature medicine. 29, 6, p. 1550-1562 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Atlases 100%
  • Immunotherapy 82%
  • Heat 68%
  • Proliferative 62%
  • Resistance 58%
  36 Scopus citations

• Proteogenomic insights suggest druggable pathways in endometrial carcinoma

  Clinical Proteomic Tumor Analysis Consortium, Sep 11 2023, In: Cancer cell. 41, 9, p. 1586-1605.e15

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Proteogenomics 100%
  • Endometrial Neoplasms 61%
  • Antigen Presentation 43%
  • Metformin 42%
  • Phosphorylation 27%
  1 Scopus citations

• Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

  Nguyen, T. D. T., Wang, Y., Bui, T. N., Lazcano, R., Ingram, D. R., Yi, M., Vakulabharanam, V., Luo, L., Pina, M. A., Karakas, C., Li, M., Kettner, N. M., Somaiah, N., Hougton, P. J., Mawlawi, O., Lazar, A. J., Hunt, K. K. & Keyomarsi, K., Mar 15 2023, In: Cancer Research. 83, 6, p. 939-955 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Retinoblastoma 100%
  • Sarcoma 79%
  • DNA 47%
  • S Phase 27%
  • 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine 25%
• 2022

  Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

  Vellano, C. P., White, M. G., Andrews, M. C., Chelvanambi, M., Witt, R. G., Daniele, J. R., Titus, M., McQuade, J. L., Conforti, F., Burton, E. M., Lastrapes, M. J., Ologun, G., Cogdill, A. P., Morad, G., Prieto, P., Lazar, A. J., Chu, Y., Han, G., Khan, M. A. W., Helmink, B., & 45 othersDavies, M. A., Amaria, R. N., Kovacs, J. J., Woodman, S. E., Patel, S., Hwu, P., Peoples, M., Lee, J. E., Cooper, Z. A., Zhu, H., Gao, G., Banerjee, H., Lau, M., Gershenwald, J. E., Lucci, A., Keung, E. Z., Ross, M. I., Pala, L., Pagan, E., Segura, R. L., Liu, Q., Borthwick, M. S., Lau, E., Yates, M. S., Westin, S. N., Wani, K., Tetzlaff, M. T., Haydu, L. E., Mahendra, M., Ma, X. Y., Logothetis, C., Kulstad, Z., Johnson, S., Hudgens, C. W., Feng, N., Federico, L., Long, G. V., Futreal, P. A., Arur, S., Tawbi, H. A., Moran, A. E., Wang, L., Heffernan, T. P., Marszalek, J. R. & Wargo, J. A., Jun 23 2022, In: Nature. 606, 7915, p. 797-803 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mitogen-Activated Protein Kinase Kinases 100%
  • Androgen Receptors 99%
  • Melanoma 22%
  • Survival 15%
  • Therapeutics 15%
  39 Scopus citations

• Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

  Wang, Y., Tian, X., Zhang, W., Zhang, Z., Lazcano, R., Hingorani, P., Roth, M. E., Gill, J. D., Harrison, D. J., Xu, Z., Jusu, S., Kannan, S., Wang, J., Lazar, A. J., Earley, E. J., Erickson, S. W., Gelb, T., Huxley, P., Lahdenranta, J., Mudd, G., & 5 othersKurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A. & Gorlick, R., Jun 2022, In: Molecular cancer therapeutics. 21, 6, p. 903-913 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Osteosarcoma 100%
  • Matrix Metalloproteinase 14 44%
  • Immunotoxins 42%
  • Surface Antigens 33%
  • Immunoconjugates 21%
  12 Scopus citations

• Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer

  Federico, L., McGrail, D. J., Bentebibel, S. E., Haymaker, C., Ravelli, A., Forget, M. A., Karpinets, T., Jiang, P., Reuben, A., Negrao, M. V., Li, J., Khairullah, R., Zhang, J., Weissferdt, A., Vaporciyan, A. A., Antonoff, M. B., Walsh, G., Lin, S. Y., Futreal, A., Wistuba, I., & 16 othersRoth, J., Byers, L. A., Gaudreau, P. O., Uraoka, N., Cruz, A. F., Dejima, H., Lazcano, R. N., Solis, L. M., Parra, E. R., Lee, J. J., Swisher, S., Cascone, T., Heymach, J. V., Sepesi, B., Gibbons, D. L. & Bernatchez, C., Jan 2022, In: Annals of Oncology. 33, 1, p. 42-56 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Non-Small Cell Lung Carcinoma 70%
  • T-Lymphocytes 48%
  • B-Lymphocytes 15%
  • Hepatitis A Virus Cellular Receptor 2 13%
  49 Scopus citations

• Highlights from the 7th Oncological Pathology Conference 'Pathological Anatomy in the context of the National Cancer Law: An overview of the Latin American experience', 15, 22 and 23 July 2022, Trujillo, Peru

  Laberiano-Fernández, C., Luján, J. M., de Carvalho Dornelas, B., Benites, M. F., Quispe, P. G., Vásquez, V. A., Espinoza, A. G., Guerra, E. G., Álvarez, G. G. A., Astigueta-Pérez, J., de Dávila, M. T. G., Zambrano, S. C., Rojas, T. V., Mariños, A., González, E. S., Lazcano, R., Lastra, R. R., Alvarado-Cabrero, I., Miller, H. G., Bardales, R. H., & 1 othersAbad-Licham, M., 2022, In: ecancermedicalscience. 16, 1462.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Peru 100%
  • Anatomy 64%
  • Pathology 49%
  • Neoplasms 25%
  • Quality Control 19%

• The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma

  Zullow, H. J., Sankar, A., Ingram, D. R., Samé Guerra, D. D., D'Avino, A. R., Collings, C. K., Lazcano, R., Wang, W. L., Liang, Y., Qi, J., Lazar, A. J. & Kadoch, C., May 5 2022, In: Molecular cell. 82, 9, p. 1737-1750.e8

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myxoid Liposarcoma 100%
  • Oncogene Proteins 73%
  • Chromatin 38%
  • Transcription Factors 32%
  • Adipogenesis 26%
  9 Scopus citations

• The immune landscape of undifferentiated pleomorphic sarcoma

  Lazcano, R., Barreto, C. M., Salazar, R., Carapeto, F., Traweek, R. S., Leung, C. H., Gite, S., Mehta, J., Ingram, D. R., Wani, K. M., Vu, K. A. T., Parra, E. R., Lu, W., Zhou, J., Witt, R. G., Cope, B., Thirasastr, P., Lin, H. Y., Scally, C. P., Conley, A. P., & 17 othersRatan, R., Livingston, J. A., Zarzour, A. M., Ludwig, J., Araujo, D., Ravi, V., Patel, S., Benjamin, R., Wargo, J., Wistuba, I. I., Somaiah, N., Roland, C. L., Keung, E. Z., Solis, L., Wang, W. L., Lazar, A. J. & Nassif, E. F., Oct 12 2022, In: Frontiers in Oncology. 12, 1008484.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sarcoma 100%
  • Disease-Free Survival 71%
  • Adenosine 29%
  • Cluster Analysis 27%
  • atezolizumab 23%
  8 Scopus citations

• The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma

  Hao, D., Han, G., Sinjab, A., Gomez-Bolanos, L. I., Lazcano, R., Serrano, A., Hernandez, S. D., Dai, E., Cao, X., Hu, J., Dang, M., Wang, R., Chu, Y., Song, X., Zhang, J., Parra, E. R., Wargo, J. A., Swisher, S. G., Cascone, T., Sepesi, B., & 11 othersFutreal, A. P., Li, M., Dubinett, S. M., Fujimoto, J., Soto, L. M. S., Wistuba, I. I., Stevenson, C. S., Spira, A., Shalapour, S., Kadara, H. & Wang, L., Nov 1 2022, In: Cancer discovery. 12, 11, p. 2626-2645 20 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenocarcinoma of Lung 100%
  • Plasma Cells 93%
  • B-Lymphocytes 72%
  • Smokers 39%
  • Ecosystem 25%
  24 Scopus citations
• 2021

  Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state

  Kochat, V., Raman, A. T., Landers, S. M., Tang, M., Schulz, J., Terranova, C., Landry, J. P., Bhalla, A. D., Beird, H. C., Wu, C. C., Jiang, Y., Mao, X., Lazcano, R., Gite, S., Ingram, D. R., Yi, M., Zhang, J., Keung, E. Z., Scally, C. P., Roland, C. L., & 13 othersHunt, K. K., Feig, B. W., Futreal, P. A., Hwu, P., Wang, W. L., Lazar, A. J., Slopis, J. M., Wilson-Robles, H., Wiener, D. J., McCutcheon, I. E., Wustefeld-Janssens, B., Rai, K. & Torres, K. E., Sep 2021, In: Acta neuropathologica. 142, 3, p. 565-590 26 p.

  Research output: Contribution to journal › Article › peer-review

  • Neurofibrosarcoma 100%
  • Neural Crest 54%
  • Phenotype 22%
  • Chromatin 16%
  • Epigenomics 16%
  12 Scopus citations

• Pathology Quality Control for Multiplex Immunofluorescence and Image Analysis Assessment in Longitudinal Studies

  Lazcano, R., Rojas, F., Laberiano, C., Hernandez, S. & Parra, E. R., Jul 30 2021, In: Frontiers in Molecular Biosciences. 8, 661222.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Quality Control 100%
  • Fluorescent Antibody Technique 88%
  • Longitudinal Studies 85%
  • Pathology 65%
  • Needle Like Crystal 54%
  5 Scopus citations

• Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases

  Marie, P. K., Haymaker, C., Parra, E. R., Kim, Y. U., Lazcano, R., Gite, S., Lorenzini, D., Wistuba, I. I., Slack Tidwell, R. S., Song, X., Foo, W. C., Maru, D. M., Chun, Y. S., Futreal, A., Kee, B., Menter, D., Solis, L., Tzeng, C. W., Parseghian, C., Raghav, K., & 8 othersMorris, V., Chang, C. C., Jenq, R., Tam, A., Bernatchez, C., Kopetz, S., Vauthey, J. N. & Overman, M. J., Jun 1 2021, In: Clinical Cancer Research. 27, 11, p. 3039-3049 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • tremelimumab 100%
  • durvalumab 96%
  • Liver Neoplasms 55%
  • Colorectal Neoplasms 44%
  • DNA Mismatch Repair 36%
  25 Scopus citations

• Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

  Terranova, C. J., Tang, M., Maitituoheti, M., Raman, A. T., Ghosh, A. K., Schulz, J., Amin, S. B., Orouji, E., Tomczak, K., Sarkar, S., Oba, J., Creasy, C., Wu, C. J., Khan, S., Lazcano, R., Wani, K., Singh, A., Barrodia, P., Zhao, D., Chen, K., & 6 othersHaydu, L. E., Wang, W. L., Lazar, A. J., Woodman, S. E., Bernatchez, C. & Rai, K., Jul 20 2021, In: Cell Reports. 36, 3, 109410.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • H3K27Me3 100%
  • H3K4Me3 97%
  • Histone 56%
  • Chromatin 46%
  • Melanoma 43%
  15 Scopus citations
• 2020

  Mechanical regulation of glycolysis via cytoskeleton architecture

  Park, J. S., Burckhardt, C. J., Lazcano, R., Solis, L. M., Isogai, T., Li, L., Chen, C. S., Gao, B., Minna, J. D., Bachoo, R., DeBerardinis, R. J. & Danuser, G., Feb 27 2020, In: Nature. 578, 7796, p. 621-626 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Glycolysis 100%
  • Cytoskeleton 95%
  • Phosphofructokinases 88%
  • Actomyosin 41%
  • Stress Fibers 39%
  300 Scopus citations